In this webinar, you will learn:

  • IVD and immunoassays, supply chain risk management considerations
  • How monoclonal and polyclonal antibody sequencing works, requirements
  • Effective production, validation, and scale-up of recombinant antibody reagents
  • Characterization of mAbs for assay design

Abstract

Polyclonal antibodies (pAbs) are well known for their robustness and epitope diversity, which makes them well suited for use in diagnostics or other assays. However, they suffer from batch-to-batch variability, or complete loss of supply when the host animal dies. Using polyclonal reagents risks costly revalidation efforts for every batch, and the eventual need to start R&D efforts from scratch when supply runs out. A well-selected cocktail of monoclonal antibodies (mAbs) can recapitulate the binding activity of a pAb. But R&D efforts to generate new mAbs that work as well as an established pAb often disappoint.

Immunoassays that rely on monoclonal antibodies (mAbs) derived from hybridomas are also prone to supply chain risk. Hybridomas often drift, die, or produce unwanted additional chains eventually leading to immunoassays with changed behaviors.

By producing recombinant monoclonal antibodies (rAbs), IVD manufacturers can ensure a constant and reliable supply of critical reagents. So the question is, how do we convert a pAb to a cocktail of recombinant mAbs? Or how can a mAb be recovered after the hybridoma has already been lost?

In this webinar, we present a single integrated workflow for antibody sequencing and recombinant expression of mAbs. We will present a case study of a successful mAb-to-rAb conversion, describe the methodology in detail, and explain how it can be used to efficiently convert a catalog of mAb or pAb reagents into recombinant antibodies.

Speaker Bios

Like this article? Get more.

Get notified of new content

Learn about upcoming webinars, new articles and special promotions.

Follow us on Linkedin

Great content, plus a little fun.

Rapid Novor

Biotechnology Research · Kitchener, Ontario · 5K followers · 51-200 employees

Talk to Our Scientists.

We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 9000+ antibodies and we are eager to help you.